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Abstract
The high prevalence of KRAS mutations and importance of the RalGEF-Ral pathway downstream
of activated K-Ras in pancreatic ductal adenocarcinoma (PDAC) emphasize the importance of
identifying novel methods by which to therapeutically target these pathways. It was recently
demonstrated that phosphorylation of RalA S194 by Aurora A kinase is critical for PDAC
tumorigenesis. We sought to evaluate the Aurora A kinase-selective inhibitor MLN8237 as a
potential indirect anti-RalA targeted therapy for PDAC. We utilized a site-specific phospho-S194
RalA antibody and determined that RalA S194 phosphorylation levels were elevated in a subset of
PDAC cell lines and human tumors relative to unmatched normal controls. Effects of MLN8237
on anchorage-independent growth in PDAC cell lines and growth of patient-derived xenografts
(PDX) were variable, with a subset of cell lines and PDX showing sensitivity. Surprisingly, RalA
S194 phosphorylation levels in PDAC cell lines or PDX tumors did not correlate with MLN8237
responsiveness. However, we identified Ki67 as a possible early predictive biomarker for response
to MLN8237 in PDAC. These results indicate that MLN8237 treatment may be effective for a
subset of PDAC patients independent of RalA S194 phosphorylation. Ki67 may be an effective
pharmacodynamic biomarker to identify response early in the course of treatment.
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INTRODUCTION
Pancreatic ducal adenocarcinoma (PDAC) is the fourth leading cause of death in the United
States accounting for approximately 37,000 deaths annually with a five year survival rate of
less than five percent (1). Gemcitabine remains the most effective treatment for patients with
locally advanced and metastatic PDAC, with only a 24% response rate and median survival
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of only 5.6 months. Therefore, there remains a crucial need for the development and
evaluation of new targeted therapies (2, 3).
The frequent mutational activation of KRAS in PDAC and critical importance of K-Ras-
driven signaling in PDAC progression has led to increased efforts to identify K-Ras-targeted
therapies. There is increasing evidence for the importance of the RalA and RalB small
GTPases in mutant Ras-driven oncogenesis (4, 5). RNAi knockdown of endogenous RalA in
PDAC cells significantly impaired anchorage-independent growth whereas knockdown of
RalB impaired Matrigel invasion in vitro and experimental metastasis in vivo (6).
Importantly, RalA-GTP and RalB-GTP levels were significantly higher in PDAC cell lines
and in patient tumors relative to normal matched and unmatched samples (6, 7). Taken
together, these studies suggest that therapeutic inhibition of Ral may be an effective therapy
for KRAS mutant PDAC.
Like Ras, Ral is a GTPase and therefore not a tractable target for direct inhibition. However,
we and others have determined that Ral growth regulatory activities are regulated by
phosphorylation. Hahn and colleagues showed that serine-threonine protein phosphatase 2A
dephosphorylation of RalA at S183 and S194 abolished RalA transforming activity (8). Two
other studies determined that S194 could be phosphorylated by Aurora A and that this
phosphorylation was essential for RalA transforming activity (9) and RalA-dependent
PDAC anchorage-independent and tumorigenic growth (10). Aurora A phosphorylation
alters RalA subcellular localization and interaction with effectors (10, 11). Activation of
Aurora A promotes mitochondrial localization of RalA and promotes mitochondrial fission
(11), which may present a mechanism for Aurora A contribution to tumorigenesis (12).
These findings suggest that protein kinas inhibitors may be an effective approach for
inhibition of Ral.
Aurora A kinas (AAK) is a member of a family of serine-threonine kinases that regulate
mitosis. A number of proteins associated with mitosis are phosphorylated by AAK through
spatially and temporally controlled mechanisms (13). Amplification of the AURKA gene is
commonly found in a number of malignancies (14–16) and overexpression of AAK is
associated with high tumor grade and poor prognosis (15, 17–20). Surprisingly, it does not
independently possess transforming activity in rodent cells or mouse models of PDAC (21,
22), suggesting the necessity to cooperate with other oncogenic pathways to promote
tumorigenesis.
This evidence suggests that targeting RalA phosphorylation with AAK inhibitors may be a
viable therapeutic option for the treatment of pancreatic cancer. MLN8237 is a novel and
selective AAK inhibitor that has entered Phase III clinical trials. We investigated the
effectiveness of MLN8237 at inhibiting anchorage-independent growth of PDAC cell lines
and patient-derived xenograft (PDX) growth in vivo. PDX models maintain heterogeneity
and allow tumor cell growth in the context of a microenvironment (23). This is especially
relevant in PDAC due to the contribution of desmoplasia to the pathology and treatment of
the disease (24, 25). The method is previously described (26–29) and involves implantation
of small tumor fragments taken from the patient and directly implanted into
immunodeficient mice. Tumors are subsequently propagated and expanded into several
animals and subjected to treatment with anticancer therapies.
In the current study, we found that S194 RalA phosphorylation was increased in a subset of
PDAC cell lines and human tumors and correlated with autophosphorylation of Aurora A
(indicative of activation). This suggested that targeting RalA phosphorylation with AAK
inhibitors may prove to be a viable therapeutic option for the treatment of pancreatic cancer.
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Therefore the goal of the current study was to investigate whether an AAK selective
inhibitor, MLN8237, may be used as a therapeutic strategy to target RalA in PDAC.
MATERIALS AND METHODS
Human pancreatic tumor cell lines
The BxPC3, MIA PaCa-2, HPAC, Panc 02.03, AsPC-1, SW1990, HPAF-II, CFPAC-1,
PANC-1, Capan-1, Capan-2, Panc 10.05, and T3M4 PDAC cell lines were obtained from
ATCC (Manassas, VA). Cell lines were passaged for fewer than six months upon acquisition
from ATCC. ATCC authentication was performed using short tandem repeat DNA profiling.
HuPT3 cells were obtained from Dan Billadeau (Mayo Clinic, Rochester, MN). No
authentication was performed on the HuPT3 cell line by the authors. The immortalized
human pancreatic duct-derived (HPNE) cells were described previously (30, 31).
Western blot analysis
Whole cell lysates were isolated in NP40 lysis buffer. Human tumor lysates from flash
frozen samples were homogenized in NP40 lysis buffer, resolved by SDS-PAGE, and
evaluated by western blot analyses with the primary antibodies: rabbit anti-phospho-RalA
(S194) (Millipore), mouse anti-RalA (BD Bioscience), rabbit anti-phospho-Aurora A (T288)
(Cell Signaling Technology), rabbit anti-Aurora A (Millipore), mouse anti-vinculin (Sigma),
mouse anti-β-tubulin (Sigma), mouse anti-HA (Covance) and species appropriate HRP-
conjugated secondary antibodies (Pierce). Membranes were subjected to detection using
ECL. Densitometry measurements were performed using ImageJ software.
Purification of recombinant GST-RalA and in vitro phosphorylation with PKA
RalA cDNA was subcloned into pGEX-2T in frame with sequences encoding an N-terminal
glutathione S-transferase (GST) tag using the BamHI site. pGEX-2T RalA, and empty
vector were transformed into Rosetta 2 bacterial expression cells. Protein expression was
induced with 1 mM IPTG. Bacterial pellets were resuspended in Triton-X-100 based lysis
buffer and sonicated. GST-bound proteins were isolated with glutathione-sepharose beads.
Five μg of purified GST or GST-RalA was incubated with 2500 U cAMP-dependent protein
kinas A (PKA) catalytic subunit (New England Biolabs) with or without 100 mM ATP for
30 min at 30°C. Reactions were separated by SDS-PAGE, transferred to polyvinylidene
fluoride (PVDF) membrane, and stained with 0.1% amido black staining solution.
Membranes were destained, imaged, and subjected to western blot analysis.
Synchronization of PDAC cell lines
To clearly visualize pT288 Aurora A protein levels, cells were synchronized prior to lysis.
Cells were treated with either dimethysulfoxide (DMSO; vehicle) or indicated
concentrations of MLN8237. Prior to harvesting and during the drug treatment cells were
synchronized by treating with 2 mM thymidine for 18 h. Thymidine was removed and cells
were released for 8 h prior to treating with 100 ng/ml nocodazole for 16 h in order to block
cells in mitosis.
Anchorage-independent growth assay
2–4 × 103 cells were seeded in a 12-well culture dish as described previously (32, 33).
DMSO or MLN8237 were included in the agar and in growth medium throughout the assay.
All conditions were seeded in triplicate. After 2–6 weeks of growth, colonies were stained
with 5 mg/ml 1-(4,5-Dimethylthiazol-2-yl)-3,5-diphenylformazan (MTT) (Sigma) and those
of >30 cells in size were scored.
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Anchorage-dependent growth assay with MTT
1–3 × 103 cells were seeded in a 96-well plate and cells were allowed to attach overnight.
DMSO or MLN8237 was added to the cells the following day and incubated for 48 h. MTT
was incubated in each well for 4 h at 37°C. The cells were lysed with DMSO and
absorbance was read at 550/490nm.
Calculation of IC50 values
IC50 values were calculated for the anchorage-dependent assays by normalizing the
absorbance in the MLN8237-treated wells to that in the DMSO wells. IC50 values were
calculated for the soft agar assays by normalizing the number of colonies in the MLN8237-
treated cells to the number of colonies in the DMSO control. The fraction of cells affected
was calculated and entered into the CalcuSyn program (Biosoft). Dose effect curves and
IC50 values were calculated.
Plasmids and retroviral infection
pSUPER.retro.blast retrovirus plasmids encoding shRNA directed against green fluorescent
protein (GFP; non-specific control) (34) and RalA have been validated and characterized
previously (35). pBabe.puro expression vectors encoding H. sapiens RalA cDNA have been
described previously (35). Site-directed mutagenesis was performed to generate
phosphorylation mutants followed by verification by sequencing. The
pBabe.hygro.HA.Aurora A T288D expression plasmid was obtained from Christopher
Counter (Duke University, Durham, NC).
Animal studies
Studies were performed in accordance with protocols approved by the University of North
Carolina Institutional Animal Care and Use Committee. The PDAC PDX model was
established as previously described (27). Briefly, de-identified tumors released by the Tissue
Procurement Core Facility under an IRB-approved protocol were mixed with Matrigel and
grafted into athymic (nu/nu) or NOD SCID gamma (NSG) mice. Tumors were allowed to
grow to maximal dimension, passaged and expanded. Tumor histology was confirmed by
hematoxylin and eosin staining prior to expansion. Nine PDX tumors were expanded in
athymic (nu/nu) mice and treatment began when the tumors reached a median volume of
97.5 mm3 (range 55–140). Tumor volume was calculated with the following formula:
(length/2)*width2. A 7.81 mg/ml MLN8237 sodium salt solution was prepared fresh before
each study in vehicle (10% 2-hydroxylpropyl-β-cyclodextrin/1% sodium bicarbonate in
sterile water). Animals were dosed via oral gavage daily with either vehicle, 10, or 30 mg/kg
(maximum tolerated dose (MTD)) MLN8237 for 28 days or until either dimension of the
tumor reached 2 cm. Tumor volume was monitored by caliper measurements. Each vehicle
and treatment group consisted of 4–6 animals. The animals were sacrificed on Day 28, 2 h
after the final dose was administered. Tumors were harvested and halved. One portion was
flash frozen and stored at −80°C and the other was fixed for 24 h in 10% formalin and
transferred to 70% ethanol for storage. For single dose studies, mice bearing tumors (median
volume 75 mm3) (3–4 animals per time point) were treated with 30 mg/kg MLN8237 and
sacrificed at the indicated times following treatment. Tumors were harvested and processed
as above. Tumor growth inhibition (TGI) was defined as >30% growth inhibition compared
to vehicle. Regression was defined as any decrease in tumor size from the treatment
initiation.
Ki67 staining of xenograft tumor tissue
Four micron sections were prepared from paraffin-embedded tumors and dewaxed in xylene
followed by graded alcohol series to water. Steam heat induced epitope recovery (SHIER)
Neel et al. Page 4













was used for the rabbit polyclonal Ki67 antibody (Vector Labs) with SHIER1 solution for
20min in the capillary gap in the upper chamber of a Black and Decker Steamer. The
immunohistochemistry procedure was automated using TechMate 500 or 1000 (Roche
Diagnostics). After staining, slides were dehydrated through an alcohol series to absolute
ethanol followed by xylene rinses. Slides were permanently coverslipped with glass
coverslips and CytoSeal (Thomas Scientific). Positive staining was indicated by the
presence of a brown chromogen (DAB-HRP) reaction product. Hematoxylin counterstain
was used to assess cell and tissue morphology. For quantitative analysis whole PDX tumors
were scanned at 20X with Olympus BX61VS equipped with a VS110 SH5 robotic stage. A
4 mm2 area chosen as representative of overall positive cell frequency was cropped and
saved as a JPEG 2000 image file. Images were analyzed using ImagePro 6.1 (Media
Cybernetics Inc.) to count the total number of pHH3 and Ki67 positive cells. Color
thresholds, area filters, and splitting tools were used to obtain a realistic segmentation of the
tumor cells. The positive percentage of Ki67 cells was obtained for each sample by dividing
the total number of Ki67 positive cells by the total number of hematoxylin stained cells.
RalA Immunofluorescence and Confocal Microscopy
Cells were seeded on coverslips, incubated overnight, treated with either vehicle of 100nM
MLN8237 for 48 h, fixed in 4% paraformaldehyde in PBS, permeabilized in 0.5% Triton
X-100/PBS, and blocked in 3% bovine serum albumin/PBS. Coverslips were then incubated
with mouse anti-RalA antibody (BD Biosciences) and fluorescent phalloidin. Confocal
images were acquired using a LSM-710 Meta laser scanning microscope (Carl Zeiss) with a
63X 1.3 numerical aperture oil immersion lens and images were processed by Photoshop
software (Adobe Systems).
RESULTS
Effects on anchorage-dependent and -independent growth of PDAC cell lines are variable
in response to MLN8237
We investigated whether MLN8237 was effective at inhibiting anchorage-dependent and -
independent growth of PDAC cell lines. AAK activity was assessed by the level of auto-
phosphorylation at threonine 288 (pT288 Aurora A), required for AAK activity, in PDAC
cell lines synchronized with a thymidine/nocodazole block (Fig. 1A). We evaluated the
effects of MLN8237 on anchorage-dependent and -independent growth in a panel of ten
PDAC cell lines with variable T288 Aurora A phosphorylation levels. Although the cell
lines exhibited a range of sensitivity in anchorage-dependent MTT assays, IC50 values from
293nM to greater than 10,000 nM, MLN8237 effects on anchorage-independent growth
were much more potent. Brdu assays were also used to assess the effects of MLN8237 on
anchorage-dependent growth in Capan-2 and MIA PaCa-2 cell lines. The IC50 values were
1372.8nM and 147.8nM in Capan-2 and MIA PaCa-2 cell lines, respectively. The cell lines
exhibited variable sensitivity to MLN8237 in soft agar with IC50 values ranging from 3.3 to
236.8nM (Table 1 and Fig. 1B, C). Following treatment with MLN8237 we observed a
concentration-dependent decrease in Aurora A T288 phosphorylation (Fig. 1D), validating
that MLN8237 was effective at inhibiting AAK activity.
MLN8237 inhibits tumor growth in a subset of PDAC PDX tumors
Because the PDX model has emerged as a better predictive model for evaluation of novel
therapeutics (23, 27), we assessed the ability of MLN8237 to inhibit tumor growth in this
model. The passaged tumors maintained the original tumor architecture observed in the
initial patient tumor (Fig. 2A), indicating that the tumor morphology remains consistent
throughout passage in the animals. Mice with early passage PDX were treated with vehicle,
10 mg/kg or 30 mg/kg MLN8237 for 28 days once tumor size reached a median size of 97.5
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mm3. Tumors were harvested for biomarker analysis on day 28 of treatment. We found that
four of the seven xenografts analyzed exhibited either regression or tumor growth inhibition
(TGI) at 30 mg/kg (Table 2 and Fig. 2B). We observed no significant responses at 10 mg/kg
(Supplementary Fig. 1B)
RalA is phosphorylated on serine 194 in a subset of human PDAC cell lines and patient
tumor samples and correlates with pT288 Aurora levels
We next sought to identify a activity-activity specific biomarker for predicting MLN8237
responsiveness in PDAC cell lines and PDX tumors. We investigated whether RalA S194
phosphorylation was a biomarker for responsiveness. In order to determine the in vivo and
clinical incidence of RalA S194 phosphorylation, we examined the phosphorylation levels
using a rabbit polyclonal antibody made against a RalA peptide sequence that contained
phosphorylated S194. We determined that this antibody was specific for RalA
phosphorylated at S194 using lysates from PANC-1 cells expressing RalA-specific shRNA
to suppress endogenous RalA expression and with ectopic expression of wild type or S194A
RalA from RNAi-insensitive cDNA expression vectors (Fig. 3A). In order to further validate
the antibody, we phosphorylated GST-RalA in vitro using the purified catalytic subunit of
PKA (previously shown to phosphorylate RalA in vitro (36)) and found that the antibody
specifically recognized purified GST-RalA in the presence of PKA and ATP
(Supplementary Fig. 2).
RalA S194 phosphorylation levels were examined in patient samples and high levels were
observed in a subset of the tumors compared to unmatched normal controls (Fig. 3C).
Lysates from a panel of PDAC cell lines were examined for S194 phosphorylation levels
and a subset of PDAC cell lines showed high levels of phosphorylation compared to non-
transformed human nestin-positive pancreatic epithelial cells (HPNE) (Fig. 3B).
Interestingly, all cell lines with high levels of pS194 RalA (BxPC3, MIAPaCa-2, Capan-2,
Panc 10-05, SW1990, and HuPT3) also had high levels of pT288 Aurora A (Fig. 1A and
Fig. 3B). However, there was not a direct correlation between MLN8237 sensitivity and the
level of basal RalA S194 phosphorylation. The correlation coefficient between pS194 RalA
levels and soft agar IC50 values was −0.41 but this was not significantly different from zero
(p-value 0.23). We observed no significant reduction in S194 RalA phosphorylation
following MLN8237 treatment. Furthermore, the trends in the changes in pS194 RalA
phosphorylations levels following treatment did not vary with MLN8237 sensitivity.
Finally, vehicle treated PDX tumors were examined to determine whether basal RalA S194
phosphorylation levels were predictive of responsiveness. We found no correlation between
RalA S194 phosphorylation levels and tumor response to MLN8237, suggesting that RalA
phosphorylation was not a predictive biomarker (Fig. 3D–E). RalA phosphorylation levels
were also examined following treatment with MLN8237 to determine whether changes in
phosphorylation occurred with treatment. We observed no consistent changes in RalA S194
phosphorylation following MLN8237 treatment (Supplementary Fig. 3) in responders
(PancT4) versus non-responders (PancT6). RalA phosphorylation was also examined in
tumors from mice subjected to short-term (4, 8, and 24 h) MLN8237 treatments and no
consistent changes were noted (data not shown).
MLN8237 treatment does not alter intracellular RalA localization in PDAC cell lines
RalA S194 phosphorylation by AAK can alter subcellular localization (10). We investigated
whether MLN8237 treatment altered the intracellular localization of RalA in four PDAC
cells lines; three with low (HuPT3, CFPAC-1, and Panc10.05) and one with high (HPAC)
IC50 values in anchorage-independent growth assays. Intracellular RalA localization
Neel et al. Page 6













remained unchanged following 48 h of treatment with 100nM MLN8237 in all four cell
lines (Fig. 4A–D).
Expression of a RalA S194 phosphomimetic mutant in PDAC cells enhances anchorage-
independent growth but does not diminish MLN8237 responsiveness
To further investigate RalA phosphorylation as a target of MLN8237 we expressed a S194
phosphomimetic mutant (S194D) as a putative Aurora A-independent variant in CFPAC-1
and MIA PaCa-2 cells (Fig. 5A) and evaluated anchorage-independent growth. As shown in
Fig. 5B, ectopic expression of the S194D RalA mutant enhanced anchorage-independent
growth two to three-fold when compared to empty vector controls. However, expression of
this Aurora A-independent RalA variant did not reduce the sensitivity of PDAC cells to
treatment with MLN8237 (Table 3 and Fig. 5B), suggesting that RalA may not be a
dominant target of MLN8237 through inhibition of Aurora A. In addition, cells expressing
S194D RalA exhibited decreases in Aurora A T288 phosphorylation similar to those seen in
vector control cells (Fig. 5C).
Ki67 is a possible early biomarker for pancreatic PDX response to MLN8237
We sought to identify a biomarker that would indicate responsiveness in tumors treated with
MLN8237. Increases in mitotic index, as quantitated by the phosphorylation levels of S10 in
histone H3, were shown to be an early pharmacodynamic biomarker of response for Aurora
A inhibition to the AAK inhibitor MLN8054 (37). Therefore, we investigated whether
mitotic index could serve as a biomarker for MLN8237 responsiveness in our model. We
examined the percentage of phosphorylated S10 histone H3-positive cells in responsive and
non-responsive tumors treated with either vehicle or 30 mg/kg MLN8237 and harvested
after 4 h, 8 h, 12 h, and 24 h. There was no significant increase in mitotic index in
responsive or non-responsive tumors (Supplementary Fig. 4A). This was also true in the
tumors treated for 28 days with vehicle or 30 mg/kg MLN8237 (Supplementary Fig. 4B),
suggesting that mitotic index was not a biomarker for responsiveness in our PDX model.
The expression of Ki67 in the nucleus is restricted to proliferating cells. Ki67 staining of
tumors is often used as a diagnostic and prognostic indicator for many tumor types,
particularly in breast and prostate tumors (38). We examined the percentage of Ki67-
positive nuclei in tumors that were responsive (PancT4) and non-responsive (PancT6) to
MLN8237 treatment. The level of Ki67-positive nuclei was examined in PancT4 and
PancT6 tumors treated with a single dose of MLN8237 (30 mg/kg) and harvested after 4 h, 8
h, and 12 h and in tumors dosed for 28 days with MLN8237 (30 mg/kg). There was a
significant reduction in the Ki67-positive nuclei in the PancT4 tumors 4 h, 8 h, and 24 h
after MLN8237 treatment (Fig. 6A, B). Although each individual harvest time point was not
statistically significant due to limited sample size, the reduction in Ki67-positive nuclei at all
time points combined was significant. There was no change in Ki67-positive nuclei
following MLN8237 treatment in the PancT6 tumors at any of the time points (Fig. 6A, B).
A similar trend was observed in the tumors treated for 28 days with MLN8237 (Fig. 6C). As
seen with the single treatment time points, there was no change in the percentage of Ki67-
positive nuclei in the PancT6 tumors following 28 days of MLN8237 treatment (Fig. 6C).
These data suggest that Ki67 may be an early pharmacodynamic biomarker to identify tumor
responsiveness after treatment with MLN8237.
DISCUSSION
The high prevalence of activating KRAS mutations in PDAC tumors and apparent KRAS
oncogene addiction in pancreatic tumors (39) (40) emphasizes the importance of identifying
anti-Ras therapies in the treatment of pancreatic cancer patients. Studies demonstrated the
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importance of RalA and, more specifically, phosphorylation at S194 by AAK, in tumor
development (6, 7, 10). The importance of RalA S194 phosphorylation in tumorigenesis
makes AAK an attractive druggable target downstream of oncogenic Ras activation. The
previous studies identifying RalA S194 phosphorylation relied primarily on ectopic
expression of phosphorylation-deficient and phosphomimetic mutants and endogenous
RalA-depleted PDAC cells. We therefore sought to evaluate endogenous RalA S194
phosphorylation levels in PDAC cell lines and human tumors using a S194 phospho-specific
antibody. Our finding that RalA S194 phosphorylation levels were elevated in a subset of
cell lines and tumors prompted us to hypothesize that anti-RalA targeted therapies may
benefit those patients exhibiting elevated phosphorylation.
The recent characterization of RalA S194 as a substrate for AAK (9, 10) and our finding that
RalA S194 phosphorylation levels correlated with Aurora A activation, as indicated by T288
phosphorylation, prompted us to investigate whether MLN8237 could be an effective anti-
RalA therapy for pancreatic cancer. Most cell lines were largely insensitive to MLN8237
using the MTT assay to assess anchorage-dependent growth. However, studies from our
laboratory and previous studies (41) have demonstrated much lower IC50 values using the
BrdU assay, which suggests that the MTT assay is not a sensitive assay for MLN8237
activity. We found that a subset of cell lines showed inhibition of anchorage-independent
growth after treatment of MLN8237 at nanomolar concentrations. However, we were unable
to correlate this with RalA S194 phosphorylation levels. AAK activity is temporally
controlled with peak activity during mitosis (42). It is possible that Aurora A
phosphorylation of RalA at S194 is strictly temporally controlled, making it difficult to
observe consistent changes following MLN8237 treatment in an asynchronous cell
population. However, our data demonstrating that overexpression of a phosphomimetic
(S194D) RalA mutant does not reduce sensitivity to MLN8237 inhibition of anchorage-
independent growth argues that perhaps RalA phosphorylation is not a critical target for
MLN8237 anti-tumor activity. We also found that RalA localization was unaffected by
treatment with MLN8237 in multiple PDAC cell lines. This is in contrast to earlier studies
using predominantly overexpression studies to assess a role for AAK in RalA localization.
Although, Counter and colleagues (10) did demonstrate localization changes of RalA with
AAK RNAi, these studies were limited to one cell line. We found no localization changes of
RalA with pharmacologic inhibition of AAK in four of four PDAC cell lines examined.
Therefore differences in AAK effects on RalA localization may be due inherent difference
between genetic and pharmacologic inhibition of AAK.
Overall, response to MLN8237 was promising in the PDX model. Of the seven PDX tumors
that we treated with 30 mg/kg (MTD) of MLN8237, three demonstrated TGI and one
exhibited regression. These data highlight the potential effectiveness of MLN8237 treatment
in a subset of patients and emphasize the importance of identifying a biomarker of response.
Although we observed that MLN8237 is effective in a subset of human tumors in our PDX
model, this response was not associated with basal phosphorylation levels of RalA at S194
or changes in mitotic index.
The upstream Aurora A activator TPX2 (targeting protein for Xenopus like-like protein 2)
was recently identified as predictive biomarker for the Aurora A-specific inhibitor MK-8745
in non-Hodgkin lymphoma cells (43). Except for this example, very few predictive
biomarkers have been characterized for AAK inhibitor responsiveness. Therefore, it is of
great interest that Ki67 does appear to be an early biomarker of response in PDAC PDX.
More studies will be needed to determine if baseline Ki67 is a predictive biomarker of
response to MLN8237.
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In conclusion, we have determined that Aurora A activity as determined by auto-
phosphorylation and RalA S194 phosphorylation levels are elevated in a subset of PDAC
cell lines and tumors. Elevated Aurora A activity correlated with high RalA S194
phosphorylation levels. We observed variable responsiveness of PDAC cell lines and PDX
to MLN8237. Basal RalA S194 phosphorylation levels or changes in RalA S194 following
MLN8237 treatment were not predictive of responsiveness, indicating that other protein
kinases or phosphatases may regulate S194 phosphorylation in PDAC cells. These data
suggest that further investigation of MLN8237 in a subset of PDAC patients is warranted,
though our preclinical data suggests that activity will be RalA-independent and that RalA
S194 phosphorylation will not be a predictive biomarker of response. However, we have
identified decreases in Ki67-positive cells as a potential early pharmacodynamic biomarker
of response to MLN8237 in PDAC. Ki67 would be attractive as it is already widely used in
clinical practice and does not suffer from the challenges of phosphospecific antibodies.
Further investigation is warranted to determine the clinical feasibility of utilizing Ki67 as a
pharmacodynamic biomarker. Finally, it appears that AAK-mediated phosphorylation of
RalA S194 is not an effective way to target RalA signaling in PDAC and further
investigation is needed to determine other potential kinases that can be targeted.
Supplementary Material
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Effects of MLN8237 on anchorage-dependent and -independent growth of PDAC cells are
variable. A, Western blot analysis of lysates from HPNE and PDAC cell lines synchronized
with a thymidine/nocodazole block using T288 Aurora A phospho-specific antibody. Total
Aurora A and vinculin are shown as loading controls. B, Representative soft agar colony
growth images from CFPAC-1 (IC50=4.6nM) and T3M4 cells (IC50=236.8nM). C,
Anchorage-independent growth of PDAC cell lines in the presence of MLN8237. Growth is
displayed in the graph as mean colony number (% DMSO control) ± SEM. D, Western blot
analysis of lysates from PDAC cell lines treated with indicated doses of MLN8237 for 48 h
and then synchronized with thymidine/nocodazole using the T288 Aurora A phospho-
specific antibody. Total Aurora A and vinculin are shown as loading controls. Data are
representative of three independent experiments.
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MLN8237 treatment inhibits the growth of a subset of PDAC PDX. A, Hematoxylin and
eosin staining of PancT6 original tumor from patient (left) and tumor from an athymic nude
mouse at passage four (right). Images are shown at 100X magnification. B, Relative tumor
growth of PDX at Day 28 treated with 30 mg/kg MLN8237 for 28 days. Data are displayed
as Log2-transformed relative (compared to initial tumor volume) tumor growth in at least
four tumor-bearing mice per treatment. Bars represent mean. TGI-tumor growth inhibition
compared to vehicle controls. * indicates significant TGI or regression (p-value ≤0.05) using
Day 28 tumor volume measurements.
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RalA is phosphorylated on serine 194 in a subset of PDAC cell lines and human tumors. A,
Western blot analysis of lysates from PANC-1 cells expressing GFP control or RalA-
specific shRNA and RNAi-insensitive empty vector, wild type RalA, or phosphorylation-
deficient (S194A) RalA using the rabbit site-specific (S194) phospho-serine RalA antibody.
pS194 RalA band present at 25 kDa (indicated by the arrow) decreases in lysates expressing
S194A RalA. B, Western blot analysis of lysates from HPNE and a panel of asynchronous
PDAC cell lines using the S194 RalA phospho-specific antibody. Total RalA and β-tubulin
are shown as loading controls. C, Western blot analysis of lysates from unmatched normal
(N) and tumor (T) patient samples using the S194 RalA phospho-specific antibody. Total
RalA and β-tubulin are shown as loading controls. D, Western blot analysis of PDX tumors
treated with vehicle and harvested on treatment day 28 using S194 RalA phospho-specific
antibody. Total RalA and β-tubulin are shown as loading controls. E, pS194 RalA to total
RalA densitometry ratio quantitation of western blots in panel D. Data are representative of
two or more independent experiments.
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MLN8237 treatment does not alter intracellular RalA localization in PDAC cell lines. A,
Representative images of HuPT3 (A), CFPAC-1 (B), Panc 10.05 (C), and HPAC (D) cells
immunostained with anti-RalA antibody and phalloidin following 48 h of treatment with
DMSO or 100nM MLN8237. Bars, 10μm. Cells are representative of 50–100 cells
visualized. Data are representative of two independent experiments.
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Expression of phospho-mimetic (S194D) RalA does not suppress the anchorage-independent
growth inhibitory effects of MLN8237. A, Western blot analysis of CFPAC-1 and MIA
PaCa-2 cells expressing either empty vector or S194D RalA using a RalA-specific antibody.
β-tubulin is shown as a loading control. B, Anchorage-independent growth of MIA PaCa-2
and CFPAC-1 cells expressing either empty vector or S194D RalA. Growth is displayed in
the graph as mean colony number ± SEM. C, Western blot analysis of MIA PaCa-2 and
CFPAC-1 cells synchronized with thymidine/nocodazole expressing either empty vector or
S194D RalA and treated with indicated doses of MLN8237 for 24 h using the T288
phospho-specific Aurora A antibody. Total Aurora A and vinculin are shown as loading
controls. Data are representative of at least two independent experiments.
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Ki67 is an early biomarker for MLN8237 responsiveness. A, Representative images of Ki67
immunostaining in PancT4 and PancT6 tumors 24h after a single dose of vehicle or 30 mg/
kg MLN8237. B, Percentage of Ki67-positive cells in responsive (PancT4) and non-
responsive (PancT6) PDX tumors harvested at indicated times after vehicle or 30 mg/kg
MLN8237 treatment. C, Percentage of Ki67-positive cells in responsive (PancT4) and non-
responsive (PancT6) PDX tumors following 28 days of treatment with vehicle or 30 mg/kg
MLN8237. Bars represent mean. * indicates significant differences (p-value <0.05) between
vehicle treatment group and MLN8237 treatment for all time points combined.
Neel et al. Page 17

























Neel et al. Page 18
Table 1






PANC 10.05 940.6 5
AsPC-1 Resistant* 7.6







greater than 10,000 nM
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Table 2
Summary of response of patient-derived xenograft tumors (based on tumor volume) following 28 day
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Table 3
Table depicting the percentage decrease in colony number in the presence of MLN8237 (50 nM and 100 nM)




Vector 32.7 ± 1.7 33.7 ± 3.6
S194D RalA 21.9 ± 3.3 20.1 ± 10.6
MIA PaCa-2
Vector 20.1 ± 10.6 4 ± 4
S194D RalA 15.6 ± 5.6 2.2 ± 1.1
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